Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
fibrosis10255 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A51305 | 35749425 | PLoS Pathog | Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19. | 2022 | Details |
| A51306 | 35735253 | Hepatol Commun | Combinations of an acetyl CoA carboxylase inhibitor with hepatic lipid modulating agents do not augment antifibrotic efficacy in preclinical models of NASH and fibrosis. | 2022 | Details |
| A51307 | 35725922 | Nat Med | Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study. | 2022 | Details |
| A51312 | 35700043 | J Clin Invest | Myeloid FoxO1 depletion attenuates hepatic inflammation and prevents nonalcoholic steatohepatitis. | 2022 | Details |
| A51313 | 35697267 | Clin Gastroenterol Hepatol | Artificial Intelligence Improves Pathologist Agreement for Fibrosis Scores in Nonalcoholic Steatohepatitis Patients. | 2022 | Details |
| A51314 | 35696549 | J Cell Physiol | Dynein light chain LC8 alleviates nonalcoholic steatohepatitis by inhibiting NF-κB signaling and reducing oxidative stress. | 2022 | Details |
| A51316 | 35675500 | Clin Transl Sci | Assessment of drug-drug interaction potential with EDP-305, a farnesoid X receptor agonist, in healthy subjects. | 2022 | Details |
| A51321 | 35625751 | Biomedicines | Influence of Type 2 Diabetes in the Association of PNPLA3 rs738409 and TM6SF2 rs58542926 Polymorphisms in NASH Advanced Liver Fibrosis. | 2022 | Details |
| A51326 | 35601801 | Therap Adv Gastroenterol | Changes in the gut microbiome associated with liver stiffness improvement in nonalcoholic steatohepatitis. | 2022 | Details |
| A51336 | 35521912 | Int J Surg Pathol | Hepatic Macrophage Types Cluster with Disease Etiology in Chronic Liver Disease and Differ Compared to Normal Liver: Implications for Their Biologic and Diagnostic Role. | 2022 | Details |
| A51340 | 35490239 | Inflamm Regen | Molecular mechanism of crosstalk between immune and metabolic systems in metabolic syndrome. | 2022 | Details |
| A51348 | 35419738 | Inflammation | Melatonin Attenuates Inflammation, Oxidative Stress, and DNA Damage in Mice with Nonalcoholic Steatohepatitis Induced by a Methionine- and Choline-Deficient Diet. | 2022 | Details |
| A51349 | 35400820 | J Clin Biochem Nutr | Effect of tocotrienol on the primary progression of nonalcoholic steatohepatitis in a mouse model. | 2021 | Details |
| A51352 | 35397697 | Dig Dis Sci | Astaxanthin Attenuates Nonalcoholic Steatohepatitis with Downregulation of Osteoprotegerin in Ovariectomized Mice Fed Choline-Deficient High-Fat Diet. | 2022 | Details |
| A51356 | 35336003 | Pharmaceutics | Safety and Pharmacokinetic Assessment of Oral Proglumide in Those with Hepatic Impairment. | 2022 | Details |
| A51359 | 35308208 | Front Pharmacol | Therapeutic Effects of Berberine on Liver Fibrosis are associated With Lipid Metabolism and Intestinal Flora. | 2022 | Details |
| A51367 | 34435180 | Matrix Biol Plus | Procollagen C-proteinase enhancer-1 (PCPE-1), a potential biomarker and therapeutic target for fibrosis. | 2021 | Details |
| A51385 | 31024205 | J Clin Exp Hepatol | Hepatocellular Carcinoma: Etiology and Current and Future Drugs. | 2019 | Details |
| A51389 | 30191979 | J Cell Physiol | Endotoxin regulates matrix genes increasing reactive oxygen species generation by intercellular communication between palmitate-treated hepatocyte and stellate cell. | 2018 | Details |
| A51390 | 35548714 | RSC Adv | SKLB023 as an iNOS inhibitor alleviated liver fibrosis by inhibiting the TGF-beta/Smad signaling pathway. | 2018 | Details |
| A51397 | 35820507 | J Hepatol | Vitamin B12 and folate decrease inflammation and fibrosis in NASH by preventing Syntaxin 17 homocysteinylation. | 2022 | Details |
| A51401 | 35789987 | Pharmacoeconomics | The Economic Burden of Non-Alcoholic Steatohepatitis: A Systematic Review. | 2022 | Details |
| A51402 | 35787976 | Cell Mol Gastroenterol Hepatol | Hydroxynonenal causes hepatocyte death by disrupting lysosomal integrity in non-alcoholic steatohepatitis. | 2022 | Details |
| A51403 | 35780059 | J Clin Lipidol | Partial lipodystrophy, severe dyslipidaemia and insulin resistant diabetes as early signs of Werner syndrome. | 2022 | Details |
| A51404 | 35779659 | J Hepatol | Digital pathology with artificial intelligence analyses provides greater insights into treatment-induced fibrosis regression in NASH. | 2022 | Details |
| A51406 | 35761808 | Exp Ther Med | Tanshinone IIA regulates the TGF-β1/Smad signaling pathway to ameliorate non-alcoholic steatohepatitis-related fibrosis. | 2022 | Details |
| A51408 | 35749855 | Bioorg Chem | Dehydromevalonolactone ameliorates liver fibrosis and inflammation by repressing activation of NLRP3 inflammasome. | 2022 | Details |
| A51409 | 35749827 | Phytomedicine | Kinsenoside alleviates inflammation and fibrosis in experimental NASH mice by suppressing the NF-κB/NLRP3 signaling pathway. | 2022 | Details |
| A51413 | 35704699 | Am J Physiol Cell Physiol | The microRNA-29 family - role in metabolism and metabolic disease. | 2022 | Details |
| A51414 | 35698494 | Vet World | Hepatoprotection of Cinnamomum burmannii ethanolic extract against high-fat and cholesterol diet in Sprague-Dawley rats (Rattus norvegicus). | 2022 | Details |
| A51426 | 35560370 | Hepatology | Lipocalin-2 Activates Hepatic stellate cells and Promotes Non-alcoholic Steatohepatitis in High-Fat Diet-Fed ob/ob mice. | 2022 | Details |
| A51428 | 35514019 | Dig Liver Dis | Rifaximin and lubiprostone mitigate liver fibrosis development by repairing gut barrier function in diet-induced rat steatohepatitis. | 2022 | Details |
| A51434 | 35421426 | J Hepatol | Mitochondrial protease ClpP supplementation ameliorates diet-induced NASH in mice. | 2022 | Details |
| A51440 | 35355667 | JGH Open | Machine learning to predict progression of non-alcoholic fatty liver to non-alcoholic steatohepatitis or fibrosis. | 2022 | Details |
| A51444 | 35340879 | Exp Ther Med | Ganoderic acid A ameliorates non-alcoholic streatohepatitis (NASH) induced by high-fat high-cholesterol diet in mice. | 2022 | Details |
| A51447 | 35326188 | Antioxidants (Basel) | Cholesterol Induces Oxidative Stress, Mitochondrial Damage and Death in Hepatic Stellate Cells to Mitigate Liver Fibrosis in Mice Model of NASH. | 2022 | Details |
| A51451 | 35310936 | iScience | Prevention and regression of megamitochondria and steatosis by blocking mitochondrial fusion in the liver. | 2022 | Details |
| A51452 | 35292349 | J Hepatol | Role of XBP1 in regulating the progression of non-alcoholic steatohepatitis. | 2022 | Details |
| A51453 | 35285180 | FEBS J | HPS protects the liver against steatosis, cell death, inflammation, and fibrosis in mice with steatohepatitis. | 2022 | Details |
| A51457 | 34693237 | JHEP Rep | Corrigendum to 'Level of MFAP4 in ascites independently predicts 1-year transplant-free survival in patients with cirrhosis' [JHEP Reports 3 (2021) 100287]. | 2021 | Details |
| A51458 | 34567824 | Liver Res | Overexpression of Galectin-1 and Galectin-3 in hepatocellular carcinoma. | 2020 | Details |
| A51477 | 30627433 | J Nutr Sci | Hot water extract of turmeric (Curcuma longa) prevents non-alcoholic steatohepatitis in mice by inhibiting hepatic oxidative stress and inflammation. | 2018 | Details |
| A51495 | 35831020 | BMJ Open Gastroenterol | Liver steatosis and metabolic dysfunction-associated fatty liver disease among HIV-positive and negative adults in urban Zambia. | 2022 | Details |
| A51496 | 35821201 | Semin Dial | Metabolic dysfunction-associated fatty liver disease (MAFLD) and advanced liver fibrosis among hemodialysis patients in a multiethnic urban population in Malaysia. | 2022 | Details |
| A51497 | 35815420 | Hepatol Res | MAFLD Directly Related to Liver Fibrosis Independent of Insulin Resistance, Hyperlipidemia, and Alcohol Intake in Morbidly Obese Patients. | 2022 | Details |
| A51498 | 35797388 | PLoS One | The performance of soluble CD163 as a non-invasive biomarker of liver damage in chronically HCV and HCV/HIV infected subjects. | 2022 | Details |
| A51502 | 35784903 | Hepatol Forum | Sustainability of diet-based moderate calorie restriction among obese patients with metabolic-associated fatty liver disease. | 2021 | Details |
| A51504 | 35770186 | Front Physiol | Extracellular Vesicles in Pathogenesis and Treatment of Metabolic Associated Fatty Liver Disease. | 2022 | Details |
| A51508 | 35741222 | Diagnostics (Basel) | Urine Proteome in Distinguishing Hepatic Steatosis in Patients with Metabolic-Associated Fatty Liver Disease. | 2022 | Details |
| A51522 | 35631255 | Nutrients | Vitamin D Status Presents Different Relationships with Severity in Metabolic-Associated Fatty Liver Disease Patients with or without Hepatitis B Infection. | 2022 | Details |
| A51524 | 35620390 | Front Endocrinol (Lausanne) | High-Sensitive CRP Correlates With the Severity of Liver Steatosis and Fibrosis in Obese Patients With Metabolic Dysfunction Associated Fatty Liver Disease. | 2022 | Details |
| A51525 | 35609821 | Clin Res Hepatol Gastroenterol | Hepatic steatosis leads to overestimation of liver stiffness measurement in both chronic hepatitis B and metabolic-associated fatty liver disease patients. | 2022 | Details |
| A51529 | 35566397 | J Clin Med | Clinical Progression of Metabolic-Associated Fatty Liver Disease Is Rare in a Danish Tertiary Liver Center. | 2022 | Details |
| A51530 | 35532410 | J Clin Endocrinol Metab | Serum Thrombospondin-2 Levels Are Closely Associated With the Severity of Metabolic Syndrome and Metabolic Associated Fatty Liver Disease. | 2022 | Details |
| A51533 | 35524581 | Adv Sci (Weinh) | Hepatic MDM2 Causes Metabolic Associated Fatty Liver Disease by Blocking Triglyceride-VLDL Secretion via ApoB Degradation. | 2022 | Details |
| A51535 | 35512760 | J Am Nutr Assoc | Evaluation of Liver Metabolism Biomarkers in Metabolic Associated Fatty Liver Disease According to Obesity Phenotype. | 2022 | Details |
| A51536 | 35491295 | Trends Endocrinol Metab | SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease. | 2022 | Details |
| A51537 | 35470984 | Hepatol Commun | Impact of the new definition of metabolic dysfunction-associated fatty liver disease on detection of significant liver fibrosis in US adolescents. | 2022 | Details |
| A51542 | 35409324 | Int J Mol Sci | Meta-Inflammation and De Novo Lipogenesis Markers Are Involved in Metabolic Associated Fatty Liver Disease Progression in BTBR ob/ob Mice. | 2022 | Details |
| A51550 | 35248669 | Gastroenterol Hepatol | Metabolic-associated fatty liver disease: From simple steatosis toward liver cirrhosis and potential complications. Proceedings of the Third Translational Hepatology Meeting, organized by the Spanish Association for the Study of the Liver (AEEH). | 2022 | Details |
| A51552 | 35233382 | J Clin Transl Hepatol | Biomarkers of Metabolic (Dysfunction)-associated Fatty Liver Disease: An Update. | 2021 | Details |
| A51559 | 35140486 | Diabetes Metab Syndr Obes | Relationship Between Serum Uric Acid-to-Creatinine Ratio and the Risk of Metabolic-Associated Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus. | 2022 | Details |
| A51562 | 35124272 | Clin Gastroenterol Hepatol | Increased risk of MAFLD and Liver Fibrosis in Inflammatory Bowel Disease Independent of Classic Metabolic Risk Factors. | 2022 | Details |
| A51566 | 35070011 | World J Hepatol | Liver function tests and metabolic-associated fatty liver disease: Changes in upper normal limits, does it really matter? | 2021 | Details |
| A51567 | 35070003 | World J Hepatol | De novo and recurrence of metabolic dysfunction-associated fatty liver disease after liver transplantation. | 2021 | Details |
| A51568 | 35057633 | Rev Esp Enferm Dig | MAFLD burden on the Spanish National Health System. A call to action. | 2022 | Details |
| A51573 | 34985050 | Eur J Gastroenterol Hepatol | Metabolic associated fatty liver disease and acute-on-chronic liver failure: common themes for common problems. | 2021 | Details |
| A51578 | 34943471 | Diagnostics (Basel) | Assessing Liver Fibrosis Using the FIB4 Index in the Community Setting. | 2021 | Details |
| A51579 | 34902216 | J Viral Hepat | Effect of liver steatosis on liver stiffness measurement in chronic hepatitis B patients with normal serum alanine aminotransferase levels: A multicentre cohort study. | 2021 | Details |
| A51581 | 34887768 | Front Pharmacol | Mechanism and Therapeutic Opportunities of Histone Modifications in Chronic Liver Disease. | 2021 | Details |
| A51584 | 34853724 | Mol Ther Nucleic Acids | Hepatocyte-derived exosomal miR-27a activateshepatic stellate cells through the inhibitionof PINK1-mediated mitophagy in MAFLD. | 2021 | Details |
| A51588 | 34760237 | Food Sci Nutr | Ameliorative effects of Cirsium japonicum extract and main component cirsimaritin in mice model of high-fat diet-induced metabolic dysfunction-associated fatty liver disease. | 2021 | Details |
| A51589 | 34751487 | Hepatol Res | Metabolic dysfunction-associated fatty liver disease and liver fibrosis: Prevalence and associated factors in the middle-aged and older US population. | 2021 | Details |
| A51600 | 35753042 | Hepatology | Fatty liver disease is not associated with increased mortality in the elderly - A prospective cohort study. | 2022 | Details |
| A51603 | 35740108 | Antioxidants (Basel) | The Beneficial Effects of Natural Extracts and Bioactive Compounds on the Gut-Liver Axis: A Promising Intervention for Alcoholic Liver Disease. | 2022 | Details |
| A51605 | 35723871 | FASEB J | Loss of SQSTM1/p62 Induces Obesity and Exacerbates Alcohol-induced Liver Injury in Aged Mice. | 2022 | Details |
| A51606 | 35721201 | Front Pharmacol | Targeting Thyroid Hormone/Thyroid Hormone Receptor Axis: An Attractive Therapy Strategy in Liver Diseases. | 2022 | Details |
| A51634 | 35467430 | Viral Immunol | Hepatitis C Virus Alters Macrophage Cholesterol Metabolism Through Interaction with Scavenger Receptors. | 2022 | Details |
| A51662 | 35138516 | Obes Surg | Liver Decompensation after Bariatric Surgery in the Absence of Cirrhosis. | 2022 | Details |
| A51670 | 35070008 | World J Hepatol | Gut dysbiosis and systemic inflammation promote cardiomyocyte abnormalities in an experimental model of steatohepatitis. | 2021 | Details |
| A51685 | 34923085 | Alcohol | Proteomic analysis of alcohol-associated hepatitis reveals glycoprotein NMB (GPNMB) as a novel hepatic and serum biomarker. | 2021 | Details |
| A51703 | 34780106 | Am J Transplant | The molecular phenotypes of injury, steatohepatitis, and fibrosis in liver transplant biopsies in the INTERLIVER study. | 2021 | Details |
| A51709 | 34722191 | J Clin Transl Hepatol | COVID-19 and Indirect Liver Injury: A Narrative Synthesis of the Evidence. | 2021 | Details |
| A51715 | 34680405 | Biomedicines | Fat: Quality, or Quantity? What Matters Most for the Progression of Metabolic Associated Fatty Liver Disease (MAFLD). | 2021 | Details |
| A51719 | 34629258 | Nutr Metab Cardiovasc Dis | Changes in markers of hepatic steatosis and fibrosis in patients with type 2 diabetes during treatment with glucagon-like peptide-1 receptor agonists. A multicenter retrospective longitudinal study. | 2021 | Details |
| A51724 | 34588748 | World J Gastroenterol | Clinical perspectives, assessment, and mechanisms of metabolic-associated fatty liver disease in patients with COVID-19. | 2021 | Details |
| A51729 | 34528879 | Turk J Gastroenterol | Evaluation of the Impact of Metabolic Syndrome on Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease. | 2021 | Details |
| A51732 | 34502295 | Int J Mol Sci | A-FABP in Metabolic Diseases and the Therapeutic Implications: An Update. | 2021 | Details |
| A51736 | 34469587 | Aliment Pharmacol Ther | Systematic review with meta-analysis: prevalence of hepatic steatosis, fibrosis and associated factors in chronic hepatitis B. | 2021 | Details |
| A51743 | 34426110 | Int Immunopharmacol | Crosstalk between hepatic stellate cells and surrounding cells in hepatic fibrosis. | 2021 | Details |
| A51752 | 34388518 | EBioMedicine | Copy number variation and expression of exportin-4 associates with severity of fibrosis in metabolic associated fatty liver disease. | 2021 | Details |
| A51762 | 34302121 | Int J Obes (Lond) | Non-hematopoietic IL-4Rα expression contributes to fructose-driven obesity and metabolic sequelae. | 2021 | Details |
| A51765 | 34279029 | J Clin Endocrinol Metab | Circulating Bile Acid Profiles: A Need for Further Examination. | 2021 | Details |
| A51773 | 34222458 | World J Clin Cases | Growth hormone cocktail improves hepatopulmonary syndrome secondary to hypopituitarism: A case report. | 2021 | Details |
| A51778 | 34141989 | Hepatol Commun | An Experimental DUAL Model of Advanced Liver Damage. | 2021 | Details |
| A51780 | 34140456 | Clin Transl Gastroenterol | Telemonitoring-Supported Exercise Training in Employees With Metabolic Syndrome Improves Liver Inflammation and Fibrosis. | 2021 | Details |
| A51785 | 34079069 | Int J Obes (Lond) | Effects of a novel polyphenol-rich plant extract on body composition, inflammation, insulin sensitivity, and glucose homeostasis in obese mice. | 2021 | Details |
| A51790 | 34064124 | Medicina (Kaunas) | Ultrasound Elastography-Cornerstone of Non-Invasive Metabolic Dysfunction-Associated Fatty Liver Disease Assessment. | 2021 | Details |
| A51794 | 34040409 | Diabetes Metab Syndr Obes | Serum Micro-RNA-122 Level as a Simple Noninvasive Marker of MAFLD Severity. | 2021 | Details |
| A51795 | 34039937 | J Clin Gastroenterol | Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Metabolic Associated Fatty Liver Disease: A Systematic Review and Meta-analysis. | 2021 | Details |